russian pharmaceutical market 2012 15 april 2013 shulyak sergey general director dsm group
Post on 30-Mar-2015
221 Views
Preview:
TRANSCRIPT
RussianPharmaceutical Market
2012
15 April 2013Shulyak SergeyGeneral DirectorDSM Group
The result of 2012 year
Source: DSM Group, audit of pharmaceutical market RF
The result of 2012 year: units
Source: DSM Group, audit of pharmaceutical market RF
Per capita consumption of medicines in Russia(pharma market)
Source: DSM Group, audit of pharmaceutical market RF
Retail segment is 74% Russian pharma market
Source: DSM Group, audit of pharmaceutical market RF
Retail segment in recent years, growing much faster
Source: DSM Group, audit of pharmaceutical market RF
Turnover of drags market is positive in EURO
Source: DSM Group, audit of pharmaceutical market RF
The largest contribution to the growth of pharma market - structural change in favor of expensive drugs
Source: DSM Group, audit of pharmaceutical market RF
Retail drug market capacity in Russia and other countries in 2012
Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources
Retail drug market capacity in Russia and other countries in 2012
Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources
Per capita consumption of medicines in the world(retail drug market)
Retail drug market = retail segment + reimbursement programSource: DSM Group, audit of pharmaceutical market RF, open sources
Rating of drug manufacturing companies:TOP 20 – 52,5%
Source: DSM Group, audit of pharmaceutical market RF
Sales value, million $.
2012
1 - NOVARTIS 1 365,9 -4,7% 5,5%2 - SANOFI 1 297,5 0,6% 5,2%3 - PHARMSTANDART 892,9 -4,3% 3,6%4 - F.HOFFMANN-LA ROCHE 766,3 4,6% 3,1%5 - TEVA PHARMACEUTICAL 739,9 1,3% 3,0%6 1 TAKEDA 716,8 10,6% 2,9%7 4 ABBOTT 702,9 26,8% 2,8%8 - BAYER 667,4 -3,3% 2,7%9 3- BERLIN-CHEMIE 667,4 6,5% 2,7%10 - MERCK 586,0 1,6% 2,4%11 2 PFIZER 566,2 12,4% 2,3%12 3- GEDEON RICHTER 563,9 -3,4% 2,3%13 1- GLAXOSMITHKLINE 546,0 5,2% 2,2%14 - SERVIER 505,8 2,2% 2,0%15 - JANSSEN PHARMACEUTICA 494,8 2,4% 2,0%16 2 STADA 428,6 8,0% 1,7%17 1- BOEHRINGER INGELHEIM 428,3 5,9% 1,7%18 1 KRKA 421,7 6,6% 1,7%19 2- ASTRAZENECA 363,5 -8,7% 1,5%20 - ASTELLAS PHARMA 351,3 20,7% 1,4%
2012 Ranking
Change Manufacturer Growth Share
Rating of ATC classification
Source: DSM Group, audit of pharmaceutical market RF
ATC level 2 Share, $
J 01 ANTIBACTERIALS FOR SYSTEMIC USE 7,0%
L01 ANTINEOPLASTIC AGENTS 6,0%
L03 IMMUNOMODULATING AGENTS 4,1%
J 05 ANTIVIRALS FOR SYSTEMIC USE 3,9%
M01 ANTI INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 3,0%
ATC level 2 Share, units
N02 ANALGESICS 10,2%
J 01 ANTIBACTERIALS FOR SYSTEMIC USE 9,3%
B05 PLASMA SUBSTITUTES AND PERFUSION SOLUTIONS 7,0%
D08 ANTISEPTICS AND DISINFECTANTS 5,1%
R01 NASAL PREPARATIONS 4,3%
Quantity of drugs in the Russian pharma market
Source: DSM Group, audit of pharmaceutical market RF
QuantityRetail segment of medicines
Segment of health care institutions
Reimbursement program
Pharma market
The full name of the drug (SKU) 22 572 15 953 5 271 27 242
The trade name of the drug 6 916 5 616 2 349 7 700
The brand name of the drug 4 769 4 179 1 804 5 368
INN 1 914 1 803 802 2 053
The drug manufacturing company 1 087 873 450 1 191
www.dsm.ru
JSC “DSM Group”Yamskogo Polya St. 7/2
Moscow, 125040Russia
Contacts:
Sergey Shulyak sshulyak@dsm.ruLilit Kotsinyan lkotsinyan@dsm.ru
top related